Umbrella review and meta-analysis of antiplatelet therapy for peripheral artery disease
British journal of surgery2019Vol. 107(1), pp. 20–32
Citations Over TimeTop 10% of 2019 papers
Graeme K. Ambler, Cherry-Ann Waldron, Ummul B. Contractor, Robert J. Hinchliffe, Christopher P. Twine
Abstract
Antiplatelet monotherapy has minimal clinical benefit for asymptomatic peripheral artery disease, and limited benefit for symptomatic disease, with a clear risk of major bleeding. There is a lack of evidence to guide antiplatelet prescribing after peripheral endovascular intervention.
Related Papers
- → Examination of the Peripheral Pulses in Patients Without Peripheral Arterial Disease(2013)1 cited
- → Women With Peripheral Arterial Disease Experience Faster Functional Decline Than Men With Peripheral Arterial Disease(2011)
- → 45 PREVALENCE OF SYMPTOMATIC PERIPHERAL ARTERIAL DISEASE, MODIFIABLE RISK FACTORS, AND APPROPRIATE USE OF DRUGS IN THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE AMONG OLDER PATIENTS OF A UNIVERSITY GENERAL MEDICINE CLINIC.(2004)
- → The prevalence of disability at the elderly with peripheral obliterative arteriopathy(2018)
- → Prevalence of Symptomatic Peripheral Arterial Disease, Modifiable Risk Factors, and Appropriate Use of Drugs in the Treatment of Peripheral Arterial Disease among Older Patients of a University General Medicine Clinic(2004)